Study: SGX301 Demonstrates Efficacy for Treatment of cutaneous T-cell lymphoma

May 06, 2021

New data from a phase 3 study evaluating SGX301 for treatment of cutaneous T-cell lymphoma (CTCL) skin symptoms was recently presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).

FDA Grants Orphan Drug Status to ITIL-168 for Melanoma
Etrasimod Demonstrates New Safety, Efficacy Data for AD in Phase 2 Study
The Emotional Effects of Acne on Teenagers and Parents
What's Hot in Biologics for Psoriasis?